EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era

Fares Qeadan, William A Barbeau

Drug and Alcohol Dependence Reports · 2026-12 · 21 · 100474

DOI: 10.1016/j.dadr.2026.100474 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug and Alcohol Dependence Reports, 2026-12. Verfasst von Fares Qeadan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson School of Health Sciences and Public Health, Loyola University Chicago, 2160 S 1st Ave, Maywood, IL 60153, USA. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This narrative review reconstructs the U.S. history of treating co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) from the rise of methadone maintenance in the 1960s through contemporary interest in immunometabolic mechanisms and repurposed therapies. Drawing on peer-reviewed literature and selected grey sources, we trace four eras including early single-substance paradigms and maintenance; federally regulated opioid treatment programs and the broader medicalization of addiction care; recognition of co-occurring disorders, parity and Affordable Care Act reforms, and uneven diffusion of medications for OUD and AUD; and a renewed metabolic framing, including preclinical, clinical, and real-world evaluation of glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists. Across eras, regulation, reimbursement, and professional authority shaped access as much as evidence, producing persistent geographic and socioeconomic inequities. Emerging GLP-1-based therapies may offer a distinctive cross-disorder adjunct, but their value for OUD/AUD remains unproven. Population benefit will require rigorous trials and delivery reforms that expand equitable access to integrated care.

Schlagwörter

Stichwörter der Autor:innen

Alcohol use disorderBuprenorphineGlucagon-like peptide-1 receptor agonistsIntegrated treatmentMethadoneNaltrexoneOpioid use disorder

Autor:innen und Institutionen

  • Parkinson School of Health Sciences and Public Health, Loyola University Chicago, 2160 S 1st Ave, Maywood, IL 60153, USA.

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Qeadan, F., & Barbeau, W. A. (2026). Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. Drug and Alcohol Dependence Reports, 21, 100474. https://doi.org/10.1016/j.dadr.2026.100474

Vancouver

Qeadan F, Barbeau WA. Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. Drug and Alcohol Dependence Reports. 2026;21:100474. doi:10.1016/j.dadr.2026.100474

BibTeX
@article{Qeadan2026,
  author = {Qeadan, Fares and Barbeau, William A},
  title = {Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era},
  journal = {Drug and Alcohol Dependence Reports},
  year = {2026},
  volume = {21},
  pages = {100474},
  doi = {10.1016/j.dadr.2026.100474}
}
Kostenlos starten →